Vincent E. Aurentz's most recent trade in Inhibikase Therapeutics Inc was a trade of 134,427 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Feb. 21, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Inhibikase Therapeutics Inc
|
Vincent E. Aurentz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 134,427 | 134,427 | - | - | Stock Option (Right to Buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 22,500 | 0 | - | - | Employee Stock Option (right to buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,500 | 0 | - | - | Employee Stock Option (right to buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 12,367 | 0 | - | - | Employee Stock Option (right to buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Dec 2024 | 7,214 | 0 | - | - | Employee Stock Option (right to buy) | |
Longboard Pharmaceuticals Inc
|
Vincent E. Aurentz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) |